AR060412A1 - Una composicion farmaceutica utilizable para inhibir o evitar la formacion no deseada de tejido fibroso y uso de la n- sulfoetilnicotinamida para inhibir o evitar la formacion no deseada de tejido fibroso - Google Patents

Una composicion farmaceutica utilizable para inhibir o evitar la formacion no deseada de tejido fibroso y uso de la n- sulfoetilnicotinamida para inhibir o evitar la formacion no deseada de tejido fibroso

Info

Publication number
AR060412A1
AR060412A1 ARP070101508A ARP070101508A AR060412A1 AR 060412 A1 AR060412 A1 AR 060412A1 AR P070101508 A ARP070101508 A AR P070101508A AR P070101508 A ARP070101508 A AR P070101508A AR 060412 A1 AR060412 A1 AR 060412A1
Authority
AR
Argentina
Prior art keywords
inhibit
avoid
formation
fiber
sulfoetilnicotinamida
Prior art date
Application number
ARP070101508A
Other languages
English (en)
Inventor
Moises Gabriel Zeitune
Ruben Martin Laguens
Original Assignee
Creactivar S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creactivar S A filed Critical Creactivar S A
Priority to ARP070101508A priority Critical patent/AR060412A1/es
Priority to PCT/MX2008/000049 priority patent/WO2008123759A1/es
Publication of AR060412A1 publication Critical patent/AR060412A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto que inhibe, evita, o previene la formacion no deseada de tejido fibroso que responde a la formula estructural (1), sulfoetilnicotinamida (NESA, ácido 2- (N-nicotinamido] etanosulfonico) y a los derivados farmacéuticamente aceptables del mismo. La composicion farmacéutica que comprende al compuesto N-sulfoetilnicotinamida (NESA) o un derivado farmacéuticamente aceptable del mismo.
ARP070101508A 2007-04-10 2007-04-10 Una composicion farmaceutica utilizable para inhibir o evitar la formacion no deseada de tejido fibroso y uso de la n- sulfoetilnicotinamida para inhibir o evitar la formacion no deseada de tejido fibroso AR060412A1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ARP070101508A AR060412A1 (es) 2007-04-10 2007-04-10 Una composicion farmaceutica utilizable para inhibir o evitar la formacion no deseada de tejido fibroso y uso de la n- sulfoetilnicotinamida para inhibir o evitar la formacion no deseada de tejido fibroso
PCT/MX2008/000049 WO2008123759A1 (es) 2007-04-10 2008-04-10 N-sulfoetilnicotinamida, composiciones farmacéuticas que la contienen y uso de las mismas para inhibir o evitar la formación no deseada de tejido fibroso

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP070101508A AR060412A1 (es) 2007-04-10 2007-04-10 Una composicion farmaceutica utilizable para inhibir o evitar la formacion no deseada de tejido fibroso y uso de la n- sulfoetilnicotinamida para inhibir o evitar la formacion no deseada de tejido fibroso

Publications (1)

Publication Number Publication Date
AR060412A1 true AR060412A1 (es) 2008-06-18

Family

ID=39590600

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101508A AR060412A1 (es) 2007-04-10 2007-04-10 Una composicion farmaceutica utilizable para inhibir o evitar la formacion no deseada de tejido fibroso y uso de la n- sulfoetilnicotinamida para inhibir o evitar la formacion no deseada de tejido fibroso

Country Status (2)

Country Link
AR (1) AR060412A1 (es)
WO (1) WO2008123759A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1408481A (en) * 1973-02-15 1975-10-01 Seperic Beta-pyridyl-carbon-amido-alkane-sulphonic acid salts their preparation and their applications
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis

Also Published As

Publication number Publication date
WO2008123759A1 (es) 2008-10-16

Similar Documents

Publication Publication Date Title
DOP2006000170A (es) Nuevos derivados de espirocromanona
ECSP099663A (es) Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y métodos para utilizar la misma
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
ECSP099755A (es) Derivados de pirrolopiridina y su uso como inhibidores de bace
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
AR071788A1 (es) Derivados de 3-aminocarbazol, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos para tratar y/o prevenir trastornos asociados con la produccion de prostaglandina e2(pge2), tales como aterosclerosis, artritis, artrosis y tumores, entre otros.
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
PE20210667A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
DOP2010000323A (es) Pirimidin-5-carboxamidas sustituidas 281
CL2008001898A1 (es) Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma.
AR045161A1 (es) Derivados de quinazolina
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
AR077014A1 (es) Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
AR049274A1 (es) Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
CL2007001784A1 (es) Compuestos derivados de benzoxazol de formula la, su composicion farmaceutica, metodo para medir in vivo depositos de amoloide empleando dicha composicion, y uso del compuesto la para preparar un medicamento, y compuesto de formula ib, y su uso como precursor en la preparacion de un compuesto marcado.
UY30289A1 (es) Derivados de la 1h-pirrol-3-carboxamida sustituida con 1-(tetrahidro-2h-piran-4-il-metil)-1h-bencimidazol, composiciones conteniéndolos, procedimientos de preparacion y aplicaciones
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
ECSP109900A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
CO6361993A2 (es) Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
DOP2009000106A (es) Compuestos de pirazol y triazol sustituídos como inhibidores de ksp
DOP2022000054A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo

Legal Events

Date Code Title Description
FB Suspension of granting procedure